Top 10 Pharmaceutical Deal Makers, 2010

 Top 10 Pharmaceutical Deal Makers, 2010

Big Pharma has had an active 2010, with a 20% increase in the number of deals concluded compared to last year according to latest figures released by MedTRACK, the biomedical database from Life Science Analytics.

Sarah Terry, president of Life Science Analytics, comments: "The huge surge in deals concluded this year has been driven by: continued back filling of pipelines; a drive into new markets with a large number of deals including companies in emerging markets; and further diversification into generics and biologics.

                            The Top 10 Dealmakers

Rank

Company

Number of Deals as of October 2010

1

Pfizer

51

2

Sanofi-Aventis

50

3

Novartis

49

4

Roche

46

5

GlaxoSmithKline

44

6

Bayer

31

7

Teva

30

8

AstraZeneca

25

9

Abbott Laboratories

20

10

Lilly

18

10

Johnson & Johnson

18

10

Merck

18

 "Not surprisingly given the companies size, Pfizer was at the top of the dealmaker list. Sanofi-Aventis is, however, most worthy of note. The company rose to second place from 14th last year, and is just one deal away from being at the top."

When looking at deals in terms of top therapy areas, oncology accounted for 24%, infectious diseases accounted for 18%, and 14% attributable to central nervous system therapies.

-Ends-

 About Life Science Analytics

Life Science Analytics, Inc.(LSA), is a biomedical data company that provides comprehensive pipeline, financial and venture information on more than 20,000 biomedical companies worldwide. Our data and research products serve executives in the pharmaceutical, biotech, and financial industries. LSA products, including MedTRACK and MedTRACK Venture Finance, provide an unbiased, accurate, independent approach to company analysis, whether for partnering or investment purposes.

Suggested Articles

After a major label expansion in December, Amarin's Vascepa is preparing a major boom in sales with its marketing team nearly scaled up.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

Data on Roche's Polivy aren't yet enough to win support from England's cost watchdogs, who rejected the medicine based on long-term…